C

Cooper Companies

Global medical devices and vision care

Technical Support Specialist Lead

Full-TimePosted on 10/19/2026
$97k - $129.3k
Senior
Bachelor's, Associate's
Trumbull, CT, USA+2 moreMore locations: Livingston, NJ, USA | Dallas, TX, USA
In Person
Customer Experience & SupportCustomer Support

About the job

Requirements
  • An associate's or bachelor's degree in a technical field, or an equivalent combination of education and experience.
  • Meets all requirements of Senior Technical Support Specialist.
  • Recognized technical expertise in assigned product lines, technologies, laboratory applications, or workflows.
  • Ability to develop technical training programs, certification standards, and competency frameworks.
  • Advanced knowledge of troubleshooting methodologies, service operations, CRM processes, and technical support best practices.
  • Expert-level proficiency with D365 CRM, service processes, asset management, incident management, and reporting tools.
  • Strong understanding of equipment installation requirements, laboratory workflows, and customer applications.
  • Experience mentoring, coaching, and developing technical personnel.
  • Ability to influence technical strategy, process improvements, and organizational best practices.
  • Leadership, presentation, facilitation, and stakeholder management skills.
  • Ability to communicate technical concepts and business value to customers, commercial teams, and executive leadership.
  • Ability to build trusted relationships with customers and internal stakeholders at all organizational levels.
  • Analytical, problem-solving, and decision-making abilities.
  • At least 7 years of relevant field service, technical support, laboratory equipment, medical device, or related technical experience.
  • Experience leading complex technical investigations, customer escalations, and cross-functional initiatives.
  • Ability to manage multiple priorities, escalations, customer requests, and strategic initiatives in a fast-paced environment.
  • Ability to maintain accurate and timely documentation of customer interactions, cases, incidents, assets, work orders, and service activities within D365 CRM.
  • Ability to comply with company policies, quality requirements, and applicable safety procedures.
Responsibilities
  • Serve as the highest-level technical escalation resource for customer, field service, and product-related issues.
  • Lead autonomous resolution of complex customer and product issues through investigation, collaboration, and corrective action implementation.
  • Establish troubleshooting methodologies, technical support standards, and best practices across the organization.
  • Establish governance and standards for D365 CRM case management, work order creation, incident classification, and asset management.
  • Ensure consistent utilization and data quality across CRM processes, workflows, and reporting.
  • Analyze technical support, asset, incident, and service data to identify trends and opportunities for operational improvement.
  • Drive continuous improvement initiatives that improve service quality, efficiency, customer satisfaction, and product reliability.
  • Develop and deliver technical training for Technical Support and Field Service personnel.
  • Train technical personnel on products, procedures, troubleshooting methodologies, and service processes.
  • Assist in developing and maintaining training materials, competency assessments, technical documentation, and knowledge management resources.
  • Partner with the internal technical training team to ensure audit readiness for training and certification programs.
  • Mentor and develop Technical Support Specialists at all levels.
  • Lead onboarding and technical competency development programs.
  • Identify organizational skill gaps and develop plans to address technical development needs.
  • Provide functional leadership, technical direction, and guidance across the Technical Support organization.
  • Promote a culture of continuous learning, knowledge sharing, and service excellence.
  • Serve as the primary technical liaison for strategic sales opportunities, product evaluations, and customer demonstrations.
  • Partner with Commercial, Sales, and Marketing teams to support business development initiatives and key customer engagements.
  • Lead technical discovery discussions to understand customer needs and recommend appropriate solutions.
  • Participate in customer meetings to explain product benefits, technical capabilities, workflows, integration requirements, and implementation strategies.
  • Provide expert consultation regarding equipment selection, laboratory workflow optimization, and operational best practices.
  • Establish standards and best practices for pre-installation assessments, site readiness reviews, and deployment planning activities in partnership with senior leadership.
  • Support complex customer conversations involving technical performance, applications, and long-term equipment strategies.
  • Partner with Product Management, Engineering, Quality, Regulatory, Sales, Marketing, and Service teams to improve products, processes, and customer outcomes.
  • Support new product introductions and lifecycle management activities.
  • Provide field and customer feedback to product development and leadership teams.
  • Use D365 CRM reporting and analytics to improve support effectiveness and operational performance.
  • Drive customer experience and service excellence initiatives.
  • Perform other duties as assigned.
  • Work primarily in an office environment or approved remote work setting, with frequent customer, field engineer, sales, and internal stakeholder interactions through phone, email, Microsoft Teams, and other remote communication tools.
  • Occasionally travel to customer sites, company facilities, training events, trade shows, customer meetings, and team meetings, with travel up to 25%.
  • Spend prolonged periods sitting and working on a computer while managing customer cases, work orders, asset records, incident records, and service documentation within D365 CRM.
Desired Qualifications
  • Previous experience serving as a trainer, mentor, technical lead, or subject matter expert.
  • Experience supporting strategic customer engagements, technical sales activities, and pre-installation planning initiatives.

About the company

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

San Ramon, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 23, 2026 Vision Centre launch accelerates six contact-lens products over several years.
  • Q3 fiscal 2026 free cash flow hit $273 million, up 66% year over year.
  • MiSight grew 20% organically, while MyDay posted double-digit growth in Q3 2026.

What critics are saying

  • Q3 2026 revenue missed by $30 million, and CooperVision destocking continues into Q4.
  • Accrued litigation liability jumped to $316.5 million on July 31, 2026.
  • Kirby McInerney opened a securities investigation after the September 9, 2026 earnings drop.

What makes Cooper Companies unique

  • CooperVision's Southampton Vision Centre unites R&D, pilot manufacturing, clinics, and commercialization.
  • CooperVision reaches 40 million people worldwide through contact lenses and myopia-control leadership.
  • CooperSurgical combines fertility, genomics, and women's-health devices under one vertically integrated platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Performance Bonus
  • Health Insurance
  • 401(k) Retirement Plan
  • Life Insurance
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Sep 24th, 2026
CooperVision opens global innovation hub in Southampton, unveils six new contact lens products

The Cooper Companies has opened The Vision Centre, a global innovation hub in Southampton, England, to accelerate contact lens development for its CooperVision business. The facility integrates research and development, clinical expertise, pilot manufacturing and commercial capabilities under one roof. CooperVision announced six product advancements across myopia control, silicone hydrogel, toric and multifocal contact lenses, with launches planned over coming years. The pipeline includes a complete family of one-day contact lenses for myopia control and a premium one-day silicone hydrogel technology. Following the announcement, COO stock gained 1.4%. Year to date, shares have declined 31.6% against the industry's 2.8% growth. The company has a market capitalisation of $10.51 billion. CooperVision's products currently reach more than 40 million people worldwide.

Associated Press
Sep 24th, 2026
Cooper Companies shares drop 14.7% after missing Q3 revenue target by $30M

Cooper Companies' shares fell 14.7% on 10 September 2026 after the medical device company reported third-quarter revenue of $1.07 billion, missing analyst expectations of $1.10 billion by $30 million. The company attributed the shortfall to its CooperVision segment, which generated $717 million in quarterly revenue, flat year-over-year. Cooper Companies said it had "proactively reduced U.S. channel inventory" in CooperVision, which would continue to impact fourth-quarter results. The share price dropped from $63.48 to close at $54.17 following the announcement. Law firm Kirby McInerney has announced an investigation into possible securities law violations by the company and its senior management. No lawsuit has been filed yet.

PR Newswire
Sep 14th, 2026
The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS.

The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS. Sep 14, 2026, 12:46 ET SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ - investors in The Cooper Companies, Inc. (NASDAQ: COO) saw the price of their shares trade down $9.31 (-14.6%) after the company reported Q3 2026 financial results that included revelations of its U.S. channel inventory destocking along with other negative surprises. The stock's move lower wiped out over $1.7 billion of the company's market capitalization. The revelations have prompted national shareholders rights firm Hagens Berman to open an investigation into whether The Cooper Companies was sufficiently transparent beforehand about its sales practices and, if not, whether it may have violated the securities laws. The firm encourages Cooper investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys. The Cooper Companies (COO) Investigation Cooper is a global medical device company with two reporting segments. The largest - CooperVision - manufactures and markets hydrogel lens products for contact lens wearers and accounted for roughly 67% of Cooper's total consolidated sales in fiscal 2025. The investigation is focused on the propriety of Cooper's statements about the mechanics contributing to CooperVision's revenue growth and its sustainability. During Cooper's June 4, 2026 Q2 2026 earnings call, management emphasized CooperVision's "solid quarter, with revenues increasing 8%, or 4% organically" and guided for CooperVision full year organic revenue growth of 3.5% to 4.5%, emphasizing that "[f]or CooperVision [...] [o]utside of Asia Pac, demand remains solid for premium products, including daily silicone hydrogel lenses as well as torics and multifocals." The next day, the price of Cooper shares traded almost 8% higher. Investors received some troubling news on September 9, 2026, when the company reported its Q3 2026 financial results. In particular, Cooper's management revealed "our legacy hydrogels were down double-digit across the board[,]" "the results in the Americas reflected CooperVision's US channel inventory reductions[,]" and "[w]e expect CooperVision revenue of $692 million to $706 million down 2% to flat organically." In response to an analyst's question during the earnings call about whether the entirety of the reduced guide for CooperVision revenue was inventory-related, CEO Albert White III said, "it's all destock [...] [m]eaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory." Another analyst expressed concern, asking "why are they destocking [...] [d]id you guys have too much inventory in the channel from past efforts to kind of prop up numbers?" The market did not take kindly to the developments and sent the price of Coopers shares down over 14% the next day to close at a 52-week low of $54.17, with several analysts reportedly downgrading their ratings and price targets. "We're focused on whether Cooper was sufficiently transparent to investors about its CooperVision sales strategies," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in Cooper and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now" Whistleblowers: Persons with non-public information regarding Cooper should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. SOURCE Hagens Berman Sobol Shapiro LLP

Yahoo Finance
Sep 14th, 2026
Cooper Companies cuts 2026 forecast as contact lens demand weakens, CooperVision revenue drops to $717M

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.

Yahoo Finance
Sep 10th, 2026
Cooper Companies Q3 earnings beat estimates at $1.15, revenues miss at $1.07B on US destocking

The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.